UCB Pharma has announced that Exemed Pharmaceuticals, a fast-growing Indian manufacturing company, will acquire UCB’S Indian production facility in Vapi. The deal includes a multi-year supply ...

In a report released today, Charles Pitman CFA from Barclays reiterated a Buy rating on UCB SA (0NZT – Research Report), with a price target of ...

Mark Bodmer and Jonathan Lewis of UCB pharma talk us though the partnering model at UCB, and how partnering can drive innovation. The world is changing and it’s no different for the ...

UCB has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 0.91, indicating that its share price is 9% ...

which continues to intrigue a substantial lineup of developers. Bellwether data rolled out this fall from UCB SA and Roche AG at the Clinical Trials in Alzheimer’s Disease meeting in Madrid.

UCB showcases decade of growth and Patient Value Strategy driving differentiated innovationBreakthrough innovation, differentiated solutions and cutting-edge pipeline to unlock growth for a decade+ ...

Barclays analyst Charles Pitman CFA maintained a Buy rating on UCB SA (0NZT – Research Report) yesterday and set a price target of €240.00. The ...